Operator

Thank you for standing by, and welcome to the 4DMedical Investor Webinar. I would now like to hand the conference over to John Hester, Senior Analyst at Bell Potter. Please go ahead.

John Hester
Bell Potter Securities Limited, Research Division

Thank you. Thank you very much, and welcome to everyone who is joining the call today. It's my pleasure to welcome you all here to today's webinar. My name is John Hester, and I'm the moderator for today's discussion. We are joined this morning by 4DMedical CEO and Founder, Dr. Andreas Fouras. Also here today is our special guest, we've got Dr. Joseph Mammarappallil, Associate Professor of Radiology, Duke University of Medicine in North Carolina. Welcome to you both.

Our discussion will center on the latest data set from 4DMedical CT:VQ exam targeted to patient selection for lung volume reduction surgery or LVRS as I will be referring to it. For those of you not familiar, LVRS is a surgical procedure performed by a thoracic surgeon to remove the most diseased overinflated lung tissue in patients with severe emphysema, allowing the remaining healthier lung to work better.

The key point is that LVRS is not suitable for all patients, and careful patient selection is very important because the procedure carries a meaningful surgical risk. With this in mind, the findings of the recent clinical trial investigating CT:VQ to aid in patient selection were presented at the recent American Thoracic Society Conference in Florida last weekend. So here to tell us